Jan 13, 2005 | NEWS
Reykjavik, ICELAND, January 13, 2005 – deCODE genetics (Nasdaq:DCGN) has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for DG041, a novel, first-in-class, orally-administered small molecule for the treatment of...
Dec 22, 2004 | NEWS
December 22, 2004 Smoking plays a dominant role in the development of the disease, but genetic factors appear to establish increased susceptibility that goes beyond the nuclear family In a paper published today in the Journal of the American Medical Association...
Dec 19, 2004 | NEWS
December 19, 2004 A major study by deCODE scientists of the geographic distribution of genetic variability in the Icelandic population has been published in the online edition of Nature Genetics. The paper by Agnar Helgason, et al., is entitled “An Icelandic example...
Dec 17, 2004 | NEWS
Reykjavik, ICELAND, December 17, 2004 – deCODE genetics (Nasdaq: DCGN) today announced the signing of an agreement under which it will conduct a Phase II information-rich clinical trial next year of a third-party compound as part of a drug development program in...
Dec 4, 2004 | NEWS
December 4, 2004 A deCODE study just published in Public Library of Science (PloS) Medicine provides the most comprehensive analyses to date of the importance of inherited risk factors for the most common forms of cancer. The results indicate that increased risk of...
Oct 19, 2004 | NEWS
• Study achieves primary endpoints; DG031 shown to be well-tolerated and to significantly reduce levels of leukotriene B4 and myeloperoxidase • First ever clinical trial based upon the isolation of a disease gene in a common disease Reykjavik, ICELAND, October 19,...
